Background: The clinical benefit of percutaneous coronary intervention (PCI) for long coronary lesions is unclear; furthermore, concerns have been raised about its safety.
Objectives: To evaluate the predictors of major adverse cardiac events (MACE) associated with PCI using a full metal jacket (FMJ), defined as overlapping drug-eluting stents (DES) measuring >60 mm in length, for very long lesions.
Methods: We enrolled 136 consecutive patients with long coronary lesions requiring FMJ in our single-center registry. The primary endpoint included the combined occurrence of all-cause death, myocardial infarction (MI), and target vessel revascularization (TVR). Demographic, clinical, angiographic, and procedural variables were evaluated using stepwise Cox regression analysis to determine independent predictors of outcome.
Results: The mean length of stent per lesion was 73.2 ± 12.3 mm and the mean reference vessel diameter was 2.9 ± 0.6 mm. Angiographic success was 96.3%. Freedom from MACE was 94.9% at 30 days and 85.3% at one year. At the one-year follow-up, the all-cause mortality rate was 3.7% (1.5% cardiac deaths), the MI rate was 3.7%, and the incidence of definite or probable stent thrombosis (ST) was 2.9%. Female gender [hazard ratio (HR), 4.40; 95% confidence interval (CI), 1.81-10.66; p = 0.001) and non-right coronary artery PCI (HR, 3.49; 95%CI, 1.42-8.59; p = 0,006) were independent predictors of MACE at one year. Freedom from adverse events at one year was higher in patients with stable angina who underwent PCI (HR, 0.33; 95%CI, 0.13-0.80; p = 0.014).
Conclusions: PCI using FMJ with DES for very long lesions was efficacious but associated with a high rate of ST at the one-year follow-up. However, the rate of cardiac mortality, nonprocedure-related MI, and MACE was relatively low. Target coronary vessel PCI, clinical presentation, and female gender are new contemporary clinical factors that appear to have adverse effects on the outcome of PCI using FMJ for long lesions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998154 | PMC |
http://dx.doi.org/10.5935/abc.20130139 | DOI Listing |
Arq Bras Cardiol
January 2025
Hospital ENCORE, Aparecida de Goiânia, GO - Brasil.
Conjoined twin patients with patent ductus arteriosus and hemodynamic repercussions have a worse prognosis. In the present case report, we demonstrate the first successful percutaneous closure of the ductus arteriosus with the Piccolo© device (Abbot Structural Heart, Plymouth, MN, USA) in this type of clinical situation.
View Article and Find Full Text PDFAm J Cardiovasc Drugs
January 2025
Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) have demonstrated promising effects in lowering cardiovascular incidents among patients with acute coronary syndrome. However, their influence on early platelet reactivity after primary percutaneous coronary intervention (PPCI) remains unclear.
Objectives: This research sought to investigate the effects of entirely human anti-PCSK9 antibodies on platelet function as measured by thrombelastography and 12-month postoperative results in patients receiving PPCI and treated with ticagrelor-based dual antiplatelet therapy.
Cardiol Rev
January 2025
Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York City, NY.
Coronary artery calcification is an impediment to percutaneous coronary interventions by obstructing the device pathway or stent deployment. To facilitate percutaneous coronary intervention in such complex lesions, high-pressure balloon dilations, atherectomy procedures, and specialty balloons are used but they all come with considerable limitations and periprocedural complications like dissection and perforation. To surpass these disadvantages, intravascular lithotripsy was introduced which acts by delivering high-pressure pulsatile sonic waves circumferentially thereby destroying the calcium deposits.
View Article and Find Full Text PDFRev Med Suisse
January 2025
Service de cardiologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
The year 2024 has witnessed substantial advancements in interventional cardiology, encompassing both coronary and structural interventions.In coronary field, trials have explored percutaneous innovations for coronary lesions, strategies for managing post‑infarction cardiogenic shock and non‑invasive approaches for guiding revascularization. The uploaded guidelines for chronic coronary syndromes emphasize individualized care, integrating modalities such as fractional flow reserve (FFR), intravascular ultrasound (IVUS), optical coherence tomography (OCT) and new teatments, including cochicine, GLP-1 receptor agonists and bempedoic acid.
View Article and Find Full Text PDFTunis Med
January 2025
Cardiology department, Habib Thameur teaching hospital, Tunis, Tunisia. Faculty of medicine of Tunis, University of Tunis El Manar.
Introduction: In recent years, advancements in chronic total occlusion (CTO) percutaneous coronary intervention (PCI) have been notable, improving procedural techniques, imaging, and management of complications.
Aim: We sought to assess the performance and the practice of a high-volume Tunisian PCI center in treating patients with a CTO.
Methods: We retrospectively evaluated data from consecutive CTO patients who underwent percutaneous revascularization from October 2019 to January 2024 at the cardiology department of Habib Thameur Teaching Hospital, Tunisia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!